Deborah B. Doroshow, MD, PhD, discusses the similarities and differences between the efficacy and safety profiles of pralsetinib and selpercatinib in patients with non–small cell lung cancer harboring RET fusions.
Deborah B. Doroshow, MD, PhD
Advertisement
Articles by Deborah B. Doroshow, MD, PhD
Deborah B. Doroshow, MD, PhD, discusses the impact of the coronavirus disease 2019 pandemic on cancer care.
Advertisement
Latest Updated Articles
Dr. Doroshow on the Impact of the COVID-19 Pandemic on Cancer CarePublished: October 7th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5